Second line options for relapsed/refractory disease COH experience with venetoclax for AL Amyloidosis

Webinar Session: Wednesday, July 1st at 6 PM (ET) Zoom Meeting

(These sessions will not be recorded due to patient involvement and HIPAA laws)

To Register HERE

Second line options for relapsed/refractory disease COH experience with venetoclax for AL Amyloidosis

Join us for an informative session on second-line treatment options for relapsed or refractory AL amyloidosis, focusing on venetoclax. Experts will explain how it works, share City of Hope experience, and discuss what patients may expect during therapy. Learn more about your options and connect with others on this journey.

Dr. Michael Rosenzweig is Chief of the Division of Multiple Myeloma and Director of the Amyloidosis Program at City of Hope. A hematologist-oncologist with expertise in plasma cell disorders, he cares for patients with multiple myeloma, Waldenström macroglobulinemia, POEMS syndrome, and all forms of amyloidosis — AL, TTR, AA, and LECT2. He trained at Boston Medical Center and Memorial Sloan Kettering, and previously directed the Amyloid Treatment and Research Program at Boston University.